Advertisement News Archives - Pharmaceutical Business review
Pharmaceutical Business review is using cookies

ContinueLearn More
Close

News

October 28, 2020

Kala Pharmaceuticals announces FDA approval of EYSUVIS for short-term treatment of dry eye disease

Kala Pharmaceuticals, a biopharmaceutical company focused on the discovery, development and commercialization of innovative therapies for diseases of the eye, today announced that the US Food and Drug Administration (FDA) has approved EYSUVIS (loteprednol etabonate ophthalmic suspension) 0.25% for the short-term (up to two weeks) treatment of the signs and symptoms of dry eye disease.

Kala Pharmaceuticals announces FDA approval of EYSUVIS for short-term treatment of dry eye disease